Rank #1909ENTA

Enanta Pharmaceuticals, Inc.

$14.00

0.79% (Daily)

Market Cap

$406.27M

Revenue

$66.98M

Rank by MCap

#1909

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Jay R. Luly Ph.D.

Headquarters

Watertown, MA

Employees

120

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human ...